| |
Normal (n = 15)
|
DM (n = 18)
|
UAP (n = 18)
|
DM + UAP (n = 21)
|
|---|
|
Age(y)
|
54.2 ± 11.4
|
56.2 ± 8.2
|
57.5 ± 10.5
|
55.3 ± 11.2
|
|
BMI(kg/m2)
|
23.7 ± 1.3
|
24.2 ± 5.3
|
25.1 ± 3.6
|
24.6 ± 4.1
|
|
Hypertension(n)
|
0
|
12*
|
14*
|
18*
|
|
Diabetes duration(y)
|
---
|
3.9 ± 1.0
|
---
|
4.1 ± 0.8
|
|
TC(mmol/l)
|
3.1 ± 0.5
|
4.6 ± 1.4*
|
4.7 ± 2.0*
|
4.9 ± 1.8*
|
|
LDL-C(mmol/l)
|
1.6 ± 0.4
|
2.9 ± 0.7*
|
3.1 ± 0.8*
|
3.0 ± 1.5*
|
|
HDL-C (mmol/l)
|
1.2 ± 0.5
|
1.2 ± 0.7
|
1.1 ± 0.8
|
1.2 ± 0.6
|
|
TG (mmol/l)
|
1.3 ± 0.7
|
2.2 ± 1.8*
|
1.9 ± 1.5*
|
2.0 ± 1.6*
|
|
WBC(× 109)
|
5.9 ± 0.9
|
7.2 ± 0.8
|
7.5 ± 0.8
|
6.8 ± 1.0
|
|
Fasting glycaemia(mg/ml)
|
4.6 ± 0.7
|
8.5 ± 2.3#*
|
5.2 ± 1.2
|
8.1 ± 1.7#*
|
|
HbA1c(%)
|
4.4 ± 0.88
|
8.4 ± 2.5#*
|
5.1 ± 1.1
|
7.8 ± 1.8#*
|
|
Medications
| | | | |
|
Statins
|
0
|
16
|
18
|
20
|
|
Aspirin
|
0
|
16
|
18
|
21
|
|
Fibrates
|
0
|
1
|
0
|
1
|
|
ACE inhibitor/ARB
|
0
|
13
|
14
|
17
|
- Results are expressed as mean ± SD. Normal: normal control subjects; DM: type 2 diabetic patients without CAD; UAP: non-diabetic patients with unstable angina pectoris; DM + UAP: type 2 diabetic patients with UAP; ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker. *p < 0.05 versus Normal; #p < 0.05 versus UAP.
